[(2R,4R,5S)-2,5-dihydroxy-6-[[(2R,4R,5S)-6-(hydroxymethyl)-5-phosphonooxy-3-[[(3R)-3-propanoyloxypentanoyl]amino]-4-[(3R)-3-propanoyloxypentanoyl]oxyoxan-2-yl]oxymethyl]-3-[[(3R)-3-hydroxypentanoyl]amino]oxan-4-yl] (3R)-3-hydroxypentanoate

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: [(2R,4R,5S)-2,5-dihydroxy-6-[[(2R,4R,5S)-6-(hydroxymethyl)-5-phosphonooxy-3-[[(3R)-3-propanoyloxypentanoyl]amino]-4-[(3R)-3-propanoyloxypentanoyl]oxyoxan-2-yl]oxymethyl]-3-[[(3R)-3-hydroxypentanoyl]amino]oxan-4-yl] (3R)-3-hydroxypentanoate
• 化学式: C₃₈H₆₅N₂O₂₂P
• 分子量: 932.9
• InChiKey: RHBZLXQMJGGSLS-CXDYNUJQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.8
• 重原子数：
  63
• 可旋转键数：
  30
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.84
• 拓扑面积：
  359
• 氢给体数：
  9
• 氢受体数：
  22

文献信息

• COMPOSITIONS AND METHODS FOR REDUCING OR PREVENTING METASTASIS
  申请人：Infectious Disease Research Institute

  公开号：US20150087615A1

  公开（公告）日：2015-03-26

  Compositions comprising glucopyranosyl lipid adjuvant (GLA) and methods for reducing or preventing the formation of cancer metastasis utilizing same are provided. The compositions may be formulated for local-regional delivery. The compositions may be substantially devoid of a cancer antigen. The treatment with GLA may be combined with treatment with a COX2 inhibitor and a beta-adrenergic blocker.
• US9463198B2
  申请人：——

  公开号：US9463198B2

  公开（公告）日：2016-10-11